ReviewCurrent pharmaceutical design2013

Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.

Luis M Valor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.